UCLA Fielding School of Public Health epidemiologist available for expert comment on Ebola outbreak in Central AfricaUCLA Fielding School of Public Health
Even after heroic medical and societal efforts finally break the back of the current COVID-19 pandemic, the global sigh of relief may not last long. The chilling reality is that viral threats are growing more common. And they’re getting deadlier.
Global health scholars have issued a clarion call about the needless loss of life expected because of a foreseeable prospect of “slow and inadequate access to supplies” to control COVID-19 in sub-Saharan Africa. They say what is unfolding now is similar to when lifesaving diagnostics and treatments came to the region long after they were available elsewhere.
Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate anti-viral drug against COVID-19.
After the Ebola virus tore through western Africa in 2015, two UC Santa Barbara researchers studied the xenophobia of the disease generated among people who had almost zero chance of being infected by it.
A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.
Interacting contagious diseases like influenza and pneumonia—and perhaps coronavirus too—follow the same complex spreading patterns as social trends, like the adoption of new slang or technologies. This new finding, published in Nature Physics, could lead to better tracking and intervention when multiple diseases spread through a population at the same time.
Robert Stahelin studies some of the world’s deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at Purdue University, examines how these viruses take advantage of human host cells.
It's no coincidence that some of the worst viral disease outbreaks in recent years -- SARS, MERS, Ebola, Marburg and likely the newly arrived 2019-nCoV virus -- originated in bats.
A device to quickly capture and identify various strains of virus has been developed, according to researchers at Penn State and New York University.
Scientists using specialized beamlines at Argonne's Structural Biology Center (SBC), a facility for macromolecular crystallography at the Advanced Photon Source, derived insights that led to the discovery of a promising new drug for Ebola.
La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).
WCS (Wildlife Conservation Society) and NIH (National Institutes of Health) scientists partnered with the Republic of Congo Ministry of Health to develop a low-cost educational outreach program and surveillance system for wildlife mortality that has continued now for over a decade.
A team devised a way to better model water’s properties. They developed a machine-learning workflow that offers accurate and computationally efficient models.
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly
The World Health Organization’s declaration today that the year-long Ebola crisis is a Public Health Emergency of International Concern is hoped to raise much-needed awareness and resources for preparedness and control efforts across the region. The decision was made following new incidents highlighting risks of repeated cross-border spread of the ongoing Ebola outbreak in the Democratic Republic of Congo.
A new risk assessment model for the transmission of Ebola accurately predicted its spread into the Republic of Uganda, according to the Kansas State University researchers who developed it. They published "Risk assessment of Ebola virus disease spreading in Uganda using a multilayer temporal network" in bioRxiv before the Uganda cases.
The Ebola outbreak in the Democratic Republic of Congo’s North Kivu province remains uncontrolled despite heroic efforts on the part of international and local responders. The spread of the disease continues to pose imminent risks of cross-border transmission. In its 11th month, the outbreak has claimed nearly 1,300 lives.
La Jolla Institute Professor Erica Ollmann Saphire, Ph.D., will lead a five-year global effort totaling up to $35 million that brings together experts from around the world to streamline and accelerate the development of immunotherapeutics against emerging and re-emerging viral threats. The international consortium is funded through the Centers of Excellence for Translational Research (CETR) program at the National Institute of Allergy and Infectious Disease), part of the National Institutes of Health (NIH).
Kansas State University researchers are helping battle most of the nation's top-priority zoonotic diseases.
A program aimed at reducing violence against women and girls by focusing on positive expressions of masculinity changed the attitudes of middle school boys who may have been prone to harassment and dating violence as they got older, according to a Rutgers University–New Brunswick and University of New Hampshire led study that was done in partnership with prevention practitioners in New England.
Researchers at McMaster University have invented a stable, affordable way to store fragile vaccines for weeks at a time at temperatures up to 40C, opening the way for life-saving anti-viral vaccines to reach remote and impoverished regions of the world.
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus.
Researchers from the University of Kent's School of Biosciences have provided evidence that a newly discovered Ebolavirus may not be as deadly as other species to humans.
Georgetown University faculty offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include WHO, Public Health Emergency of International Concern (PHEIC), International Health Regulations, infectious disease control and treatment, vaccine development, clinical trials, and global health security and law.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.
Aid workers put their lives on the line to treat patients with Ebola. Can robots help make their jobs a little easier and allow more people to survive the disease? Bill Smart, professor of robotics at Oregon State University, is exploring how robots may be most useful during disease outbreaks.
A detailed analysis of blood samples from Ebola patients is providing clues about the progression of the effects of the virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.
A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) has begun in the United States at Cincinnati Children’s Hospital Medical Center. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts. Scientists at Texas Biomedical Research Institute were part of a nationwide collaborative with scientists at Gladstone Institutes, UC San Francisco and Georgia State University for a study recently published in the journal Cell.
Ebola virus (green) infects human cells much more easily when you remove the protective RBBP6 protein (compare left to right). Researchers have discovered a human protein that helps fight the Ebola virus and could one day lead to an effective therapy against the deadly disease, according to a new study from Northwestern University, Georgia State University, University of California, San Francisco (UCSF) and the Gladstone Institutes published today, Dec.
Texas Biomed researchers – in collaboration with the University of Iowa – are trying to find out how malarial infections impact people exposed to Ebola virus. Both diseases are endemic in that region.
A novel synthetic DNA vaccine developed based on technology pioneered by Wistar scientists offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research.
A new study from the NYU College of Global Public Health and NYU Tandon School of Engineering, published in Nature Digital Medicine, used text message surveys to determine in real time how people used maternal health services during a recent Ebola outbreak and measured a drop in hospital-based births during the outbreak.
Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
Geneticist Jason Ladner talks about the study, which underscores the need for focused prevention efforts among survivors and better capacity to detect new cases of the deadly virus.
A new study at Texas Biomedical Research Institute is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication.
A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.
WASHINGTON — Georgetown University professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include infectious disease control and treatment, vaccine development, clinical trials, global health security, and international health regulations. To schedule an interview, please contact Karen Teber at km463@georgetown.